Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01550471 · ClinicalTrials.gov registry record · Phase 4

Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis

A Phase 4 study of Asthma and Allergic Rhinitis, sponsored by West Penn Allegheny Health System.

Completed
Registry status
Phase 4
Development phase
22
Enrollment target
2
Study locations

NCT01550471 is a Phase 4 study of Asthma and Allergic Rhinitis that has completed, run by West Penn Allegheny Health System. The registered enrollment target is 22 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01550471, a Phase 4 study of Asthma and Allergic Rhinitis, has completed, sponsored by West Penn Allegheny Health System.

COMPLETED
Registry status
Phase 4
Development phase
22 participants
Enrollment target
2
Study locations

Study Summary

This study will provide the clinicians guidance on the safest combination of inhaled and nasal corticosteroids for children with mild asthma and allergic rhinitis respectively; however, one safety concern is that these products are independently known to have dose-related effects on short term and intermediate term growth. Knemometry is a non invasive technique for measuring short-term lower leg growth in children and is currently the method of choice in growth studies of short duration. Subjects will be seen on a weekly basis for 18 weeks and at each visit, lower leg length will be measured using knemometry.

Conditions Studied

Asthma Allergic Rhinitis

Interventions

  • DRUG Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo
  • DRUG Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase
  • DRUG QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo
  • DRUG QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris
  • DRUG Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase

Study Locations (2)

Pennsylvania

  • Pediatric Alliance-Greentree Division - Green Tree
  • Alleghney General Hospital - Pittsburgh

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2012-03
Est. Completion 2015-08
Phase Phase 4

Sponsor

West Penn Allegheny Health System

14 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01550471

The ClinicalTrials.gov registry entry for NCT01550471 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (99% lower). The listed sponsor is West Penn Allegheny Health System, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Asthma appearing as the primary indexed condition, and to 5 interventions - of which Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo is the first listed.

NCT01550471 reports 2 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01550471 about?

NCT01550471 is a clinical study titled "Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis". This study will provide the clinicians guidance on the safest combination of inhaled and nasal corticosteroids for children with mild asthma and allergic rhinitis respectively; however, one safety concern is that these products are independently known to have dose-related effects on short term and i...

What is the current status of trial NCT01550471?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2012-03. Estimated completion is 2015-08.

What conditions does trial NCT01550471 study?

This clinical trial studies the following conditions: Asthma, Allergic Rhinitis.

What interventions are being tested in trial NCT01550471?

The interventions under investigation include: Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo (DRUG), Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase (DRUG), QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo (DRUG), QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris (DRUG), Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase (DRUG).

Who is sponsoring clinical trial NCT01550471?

This trial is sponsored by West Penn Allegheny Health System, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01550471 being conducted?

This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Asthma

All registered trials for this condition

Allergic Rhinitis

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.